MedTrace Logo

Evaluating the Human Immune Response to the JYNNEOS Vaccine

NCT06366672 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-10-16

No results posted yet for this study

Summary

This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.

Conditions

  • Vaccinia
  • Virus Diseases

Interventions

BIOLOGICAL

JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection

live, nonreplicating vaccine delivered according to the FDA approved package insert

PROCEDURE

Phlebotomy

Research blood draw

PROCEDURE

Research bronchoscopy

Outpatient research bronchoscopy with bronchoalveolar lavage and endobronchial biopsy performed with conscious sedation.

PROCEDURE

Skin punch biopsy

Skin punch biopsy performed with topical anesthesia.

PROCEDURE

Bone marrow aspiration

Bone marrow aspiration performed with local anesthesia.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Philip Mudd, MD, PhD · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2026-09-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06366672 on ClinicalTrials.gov